| Drug Name |
Rufinamide |
| Drug ID |
BADD_D01977 |
| Description |
Rufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy. Clinical trials suggest its efficacy in the treatment of partial seizures. |
| Indications and Usage |
Adjunct therapy for treatment of seizures associated with Lennox-Gastaut syndrome. |
| Marketing Status |
approved |
| ATC Code |
N03AF03 |
| DrugBank ID |
DB06201
|
| KEGG ID |
D05775
|
| MeSH ID |
C079703
|
| PubChem ID |
129228
|
| TTD Drug ID |
D0MD2L
|
| NDC Product Code |
66039-881; 42571-392; 59651-616; 59651-617; 68462-714; 71428-009; 31722-599; 62856-582; 62856-584; 68180-802; 62856-583; 68180-804; 14501-0058; 50923-0614; 42571-391; 0378-2331; 68180-797; 68462-713; 0054-0528; 51148-010; 65977-0068; 69452-223; 0054-0426; 46438-0661; 46438-0662; 69766-050; 31722-598; 0378-2330; 51148-009; 66005-0037; 59651-563; 68180-803; 0054-0425; 67877-673; 51148-008 |
| UNII |
WFW942PR79
|
| Synonyms |
rufinamide | 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide | CGP 33101 | CGP-33101 | Inovelon |